Project Grant R01EY036220

Award Date 5/1/24
Completion Date 4/30/29
Dollars Obligated $1.7M
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This $499,116 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to develop stem cell-derived neuronal relays to regenerate the optic nerve and restore vision. The key objectives are to: 1) measure the functional recovery from long-term optic nerve grafted neural stem cells in the injured visual system, 2) investigate the role of guidance cues on directing neuronal relay axons through the optic chiasm, and 3) target the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is providing $426,938 to Virginia Commonwealth University to explore the role of a novel glutamate-driven signaling pathway initiated in maturing oligodendrocytes through the glutamate transporter GLT-1/EAAT2. This research aims to characterize the mechanisms downstream of...
This $665,243 Project Grant, awarded by the National Eye Institute under the Vision Research program (CFDA 93.867), supports research at The Ohio State University to investigate the use of polarized myeloid cells for enhancing retinal ganglion cell (RGC) survival and optic nerve regeneration. The research aims to elucidate the factors secreted by interleukin-4 and granulocyte-colony stimulating factor polarized bone marrow neutrophils that promote neuroprotective and pro-regenerative effects,...
This federal Project Grant award from the National Eye Institute (CFDA Program 93.867 - Vision Research) provides funding to conduct research on the mechanisms underlying the pro-regenerative effects of conditioning lens injury on retinal ganglion cells (RGCs) and their axon regeneration. The $168,396 award to the Regents of the University of Michigan will support investigations focused on two key aims: Evaluating the role of α-crystallins, which were identified as top candidate proteins...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
This federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding of $393,008 to the University of California, Davis to conduct research focused on understanding the mechanisms underlying successful axonal regeneration in the retinal ganglion cells of the frog Xenopus laevis. The key goals of this 5-year research project are to systematically dissect the intrinsic pathways involving the genes DLK and SARM1 that facilitate axon regeneration, as well...
This Project Grant award, valued at $132,597.00 and provided by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), supports research aimed at improving retinal ganglion cell (RGC) replacement therapies for glaucoma. The research project, conducted by The Schepens Eye Research Institute, Inc., a non-profit organization in Boston, Massachusetts, focuses on investigating the role of neural activity in regulating the integration of transplanted RGCs within the host...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to evaluate the regenerative potential of human retinal ganglion cells (RGCs) and the regrowth of the optic nerve. The $147,486 award to The Johns Hopkins University aims to identify intrinsic factors that regulate RGC survival, axonal outgrowth, and functional recovery in a regenerative animal model, the zebrafish. The research will also test how modulation of these...
This Project Grant award, provided by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), supports research on how neuronal activity and neurotransmitters, specifically glutamate, influence retinal angiogenesis and blood-retina barrier (BRB) maturation. The $248,999 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University will fund a 3-year study to investigate the mechanisms by which synaptic glutamate release regulates deep...
This Project Grant award from the National Eye Institute (NEI), part of the U.S. Department of Health and Human Services, under the Vision Research (CFDA 93.867) program, provides $500,500 to support research on the role of retinal ganglion cells in shaping the identity and function of neurons in the superior colliculus visual processing region. The key objectives are to: 1) determine how retinal input influences the morphology and transcriptional profiles of genetically-defined neuron...

PROMOTING MYELINATION OF REGENERATING AXONS FOR VISION RESTORATION - ABSTRACT/PROJECT SUMMARY MYELINATION FACILITATES RAPID AXONAL CONDUCTION, ENABLING EFFICIENT COMMUNICATION ACROSS DIFFERENT PARTS OF THE NERVOUS SYSTEM. DEMYELINATION ASSOCIATED WITH CNS TRAUMA OR DISEASES SUCH AS MULTIPLE SCLEROSIS (MS) AND GLAUCOMA CONTRIBUTES SIGNIFICANTLY TO BEHAVIORAL DEFICITS. DESPITE TREMENDOUS PROGRESS IN UNDERSTANDING REGULATORY MECHANISMS OF MYELINATION, THERE ARE NO PRO-MYELINATION TREATMENTS IN THE CLINICAL SETTING. IN OUR RECENT STUDIES, USING OPTIC NERVE/TRACT INJURY MODELS, WE DISCOVERED THAT INJURED AXONS COULD REGENERATE FOLLOWING INTERVENTION TO ELEVATE THE REGENERATIVE ABILITY OF RETINAL GANGLION CELLS (RGCS), YET THESE REGENERATED AXONS FAIL TO BE MYELINATED. FURTHER, WE SHOWED THAT OLIGODENDROCYTE PRECURSOR CELLS (OPCS) DO PROLIFERATE BUT FAIL TO DIFFERENTIATE AND MATURE INTO MYELINATING OLIGODENDROCYTES IN RESPONSE TO ONC. WITH THESE UNIQUE MODELS, WE FURTHER DEMONSTRATED THAT BLOCKADE OF MUSCARINIC RECEPTOR 1 (M1R, OR CHRM1) OR GPR17 PROMOTED OPC DIFFERENTIATION WHILE DEPLETING ACTIVATED MICROGLIA FACILITATED THE MATURATION OR SURVIVAL OF NEWLY FORMED OLIGODENDROCYTES. THUS, AT LEAST TWO OVERARCHING MECHANISMS CONTRIBUTE TO THE OBSERVED MYELINATION FAILURE: OPC INTRINSIC MECHANISMS PREVENTING OPC DIFFERENTIATION, AND MICROGLIA-RELEVANT FACTORS INHIBITING THE FORMATION OF MATURE OLIGODENDROCYTES BY UNKNOWN MECHANISM(S). IMPORTANTLY, TREATMENTS ACTING ON THESE MECHANISMS PROMOTED DE NOVO MYELINATION OF REGENERATED AXONS AND POINT TO POTENTIAL TRANSLATABLE PRO- MYELINATION STRATEGIES. IN THIS APPLICATION, FOLLOWING UP WITH THESE INITIAL FINDINGS, WE WILL INVESTIGATE THE FOLLOWING QUESTIONS: HOW DO M1R AND GPR17 REGULATE OPC DIFFERENTIATION? DO THEY WORK WITHIN THE SAME SIGNALING PATHWAY(S)? HOW DO ACTIVATED MICROGLIA AFFECT OLIGODENDROCYTES? DOES TREATMENT-INDUCED DE NOVO MYELINATION IMPROVE BEHAVIORAL OUTCOME(S)? WE EXPECT THAT OUR STUDIES WILL INFORM THE MECHANISMS AND THERAPEUTIC POTENTIAL OF MYELINATION REGENERATION AND VISUAL RESTORATION.

Posted 4/4/24, 12:00 AM